Anokion Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
Anokion is a clinical-stage biotechnology company focused on autoimmune diseases, aiming to restore normal immune tolerance. Its research targets both common and rare conditions, including celiac disease, multiple sclerosis, and type 1 diabetes. The company uses an immune-based platform that engages pathways in the liver to reestablish immune tolerance and address the root causes of autoimmune dysfunction. Described as Swiss in origin, Anokion is listed at a Cambridge, Massachusetts address in the United States. In September 2023, Anokion reported clinical progress for its KAN-101 and ANK-700 programs, signaling advancement in its therapeutic efforts. Operating within the biotechnology research sector, the company seeks to translate immune-tolerance concepts into treatments for patients affected by autoimmune diseases.